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A  membranous  nephropathy  case:  Is  it  related  to
sulfasalazine?
Un  nefropatía  membranosa  Caso:  ¿Está  relacionado  con
sulfasalazina?
Dear Editor, Although rare, case reports blaming sulfasalazine in the
pathogenesis of parenchymal kidney injury, exist. Neverthe-In adult age group, the cause of membranous glomeru-
lonephritis (MG) cannot be detected in about 75% of the
less, the US FDA placed a warning within the prescribing
information for mesalazine products that stated “It is rec-patients. These cases are deﬁned as idiopathic (primary) MG.
MG associated with drugs and other diseases are deﬁned as
secondary MG.
Penicillamine and gold salts, formerly used in the treat-
ment of rheumatoid arthritis (RA), are responsible for
the development of MG. Amyloidosis, analgesic nephropa-
thy, glomerulonephritis and rheumatoid vasculitis can be
observed in RA.
In the literature sulfasalazine was reported to cause inter-
stitial nephritis, nephrotic syndrome, acute renal failure,
non-nephrotic proteinuria, hematuria, and leucocyturia.1–4
Sulfasalazine 2000 mg/day, hydroxychloroquine, prednisolone
5 mg/day was started for a 55 year old non-diabetic man  who
was diagnosed as rheumatoid arthritis a year ago. He did
not have a history of nonsteroidal antiinﬂamatory drug use.
Proteinuria was detected a month later. Daily protein excre-
tion was 14,725 mg/day and serum albumin was 2.8 g/dl. On
physical examination, the patient was normotensive and had
pitting oedema in his legs. The patient’s blood urea nitro-
gen and creatinine level and C3, C4 was in normal range
and HBsAg, AntiHCV, p-ANCA and c-ANCA was found to
be negative. ANA was positive, but anti-ds DNA was found
to be negative. Duodenal biopsy was negative for amyloid
and percutaneous kidney biopsy was performed. In light
microscopic examination, mild thickening of the glomeru-
lar basement membrane, mild interstitial inﬂammatory cell
inﬁltration and hyaline material accumulation in some tubu-
lar spaces was observed. By immunoﬂuorescence microscopy
strong linear/granular IgG and complement deposition and
mild granular, C3, C1q and kappa deposition in glomerular
basal membranes was detected. These pathological ﬁndings
suggested the diagnosis of membranous glomerulonephri-
tis anti-phospholipase A2 receptor antibodies were negative.
Considering this condition to be related to sulfasalazine, treat-
ment was dropped out and prednisolone dosage was increased
as 20 mg/day. In follow-up, two months later, 24-h urine pro-
tein excretion was found to be 389 mg/day and steroid dosage
was tapered gradually. He is now being followed without pro-
teinuria.





3ommended that all patients have an evaluation of renal
function prior to initiation of therapy and periodically while
on treatment”.5
5-Aminosalicylate (5-ASA) is blamed for the nephrotoxicity
of these drugs. Nephrotoxicity is thought to be idiosyncratic
rather than dose-related.6 Cases reported in the literature
were mainly in the form of progressive interstitial nephritis.
Following cessation of treatment, improvement of renal func-
tion can be observed in some cases, while steroid treatment
can be indicated if improvement is not observed.7
In a cohort of ulcerative colitis 6 patients were reported to
develop nephrotic syndrome. 3 of these patients were using
mesalasine while 2 were using sulfasalazine and one patient
was using both. In histological evaluation of the patients, 5
had minimal change disease and one patient had focal seg-
mental glomerulosclerosis. All of the patients improved with
steroid treatment.8 The pathogenesis of nephrotic syndrome
associated with the use of sulfasalazine is not understood yet.9
The patient was also using hydroxychloroquine. This drug
continued and remission of proteinuria existed, so the cause is
not probably this drug. Also rheumatologic diseases can cause
MN but proteinuria remission after discontinuation of the drug
excluded this possibility.
In our case, the histopathologic diagnosis was membra-
nous glomerulonephritis and this varies from case reports in
the literature.
Drugs are one of the important causes of secondary mem-
branous glomerulonephritis. By presenting this case we  want
to remind that sulfasalazine may be a cause of secondary
membranous glomerulonephritis. e  f  e  r  e  n  c  e  s
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Complete  remission  of nephrotic  syndrome  in a woman
























semisión  completa  de  síndrome  n
enal  por  ﬁebre  mediterránea  fami
ear Editor,
hronic kidney disease due to AA amyloidosis is one of the
ain complications of Familial Mediterranean Fever (FMF).1
n 2009, in the journal Nefrología,  we presented the case of a
8-year-old woman of Armenian origin with severe nephrotic
yndrome due to AA amyloidosis as a form of onset of FMF
with heterozygous M680I and M694V mutations in the MEFV
ene). Given the severity of her proteinuria at diagnosis,
eterioration in renal function and intolerance to antiprotein-
ric drugs, we started treatment with colchicine, at doses of
.5 mg/8 h/day, and inﬂiximab, at doses of 5 mg/kg IV at base-
ine, at 2 weeks and subsequently every 2 months. In the
linical follow-up performed in the ﬁrst year of treatment to
valuate her response to this, we reported partial remission:
linical improvement and improvement in renal function, but
ith persistent nephrotic proteinuria.2
In this report we  describe her mid-term clinical course. In
he following 6 years, the patient has remained asymptomatic
ith no new episodes of hydropic decompensation or hos-
ital admissions. Table 1 shows the clinical course of both
er laboratory values and the treatment followed. Starting
rom the second year of treatment, colchicine was sustained Please cite this article as: Heras M, Saiz A, Fernández-Reyes MJ, Mol
índrome nefrótico en mujer con amiloidosis renal por ﬁebre mediterrótico  en  mujer  con  amiloidosis
r
continuously at doses of 1 mg/day. Given that her proteinuria
progressively decreased, inﬂiximab doses were increasingly
spaced out, to intervals of 4–6 months, and this treatment was
permanently suspended in 2011.
As a result of combination therapy with colchicine and
inﬂiximab, in the acute phase of diagnosis of AA amyloidosis
due to FMF,  clinical improvement and improvement in renal
function were achieved, but nephrotic proteinuria persisted.
Subsequent follow-up required us to modify our initial conclu-
sions: her clinical improvement was maintained, without any
new hydropic decompensation, in the context of resolution of
her proteinuria.
Treatment with colchicine is effective in preventing amy-
loidosis in Armenian patients with FMF.3 In cases of colchicine
resistance or intolerance, anti-TNF agents may be effective to
treat these patients and manage symptoms associated with
FMF.4,5 In our case, given the initial severity of nephrotic
syndrome, together with the ﬁndings of AA amyloid in the
renal parenchyma and the M694V mutation associated with
the most serious cases, combination therapy was decided
upon, with a partial response in the ﬁrst year and subse-
quently a complete response sustained over time. Perhaps
this combination treatment, as it prevented the onset ofina A, Astrid Rodríguez M, Callejas R. Remisión completa de
ánea familiar. Nefrologia. 2016;36:331–332.
